1. Home
  2. EQS vs GTBP Comparison

EQS vs GTBP Comparison

Compare EQS & GTBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Equus Total Return Inc.

EQS

Equus Total Return Inc.

HOLD

Current Price

$0.90

Market Cap

12.3M

Sector

Finance

ML Signal

HOLD

Logo GT Biopharma Inc.

GTBP

GT Biopharma Inc.

HOLD

Current Price

$7.25

Market Cap

12.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EQS
GTBP
Founded
1991
1965
Country
United States
United States
Employees
N/A
N/A
Industry
Finance Companies
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
12.3M
12.4M
IPO Year
1995
2016

Fundamental Metrics

Financial Performance
Metric
EQS
GTBP
Price
$0.90
$7.25
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
8.8K
★ 37.7K
Earning Date
01-01-0001
11-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 3.75
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.77
$0.22
52 Week High
$2.05
$287.50

Technical Indicators

Market Signals
Indicator
EQS
GTBP
Relative Strength Index (RSI) 51.99 37.50
Support Level $0.77 $6.73
Resistance Level $1.04 $7.97
Average True Range (ATR) 0.08 0.56
MACD 0.01 1.05
Stochastic Oscillator 61.52 61.47

Price Performance

Historical Comparison
EQS
GTBP

About EQS Equus Total Return Inc.

Equus Total Return Inc is a United States-based closed-end management investment company. The company invests mainly in companies pursuing growth either through acquisition or organically, leveraged buyouts, management buyouts, and recapitalizations of existing businesses or special situations, and achieves capital appreciation by making investments in equity and equity-oriented securities issued by privately-owned companies or smaller public companies in transactions.

About GTBP GT Biopharma Inc.

GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. The company is engaged in discovering, developing, and commercializing therapeutics from its proprietary product platform across various disease areas, mainly focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platform offers immuno-oncology products designed to treat hematologic malignancies, sarcoma, and solid tumors.

Share on Social Networks: